Lifecore Biomedical, Inc. - Common Stock (LFCR)
5.3300
-1.4800 (-21.73%)
NASDAQ · Last Trade: Apr 4th, 7:44 PM EDT
Detailed Quote
Previous Close | 6.810 |
---|---|
Open | 6.300 |
Bid | 5.340 |
Ask | 5.380 |
Day's Range | 4.910 - 6.410 |
52 Week Range | 3.679 - 7.990 |
Volume | 920,994 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 251,947 |
Chart
About Lifecore Biomedical, Inc. - Common Stock (LFCR)
Lifecore Biomedical, Inc. is a company specializing in the development and manufacturing of advanced biomaterials and medical devices. They focus on products that improve patient outcomes, particularly in the fields of orthopedic, ophthalmic, and surgical applications. Lifecore's expertise lies in the production of hyaluronic acid and its derivatives, which are used in a variety of therapeutic and aesthetic treatments. The company collaborates with healthcare professionals and organizations to innovate and enhance the effectiveness of their biomedical solutions, contributing to advancements in medical technology and patient care. Read More
News & Press Releases
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via Chartmill · April 4, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.
Via Chartmill · April 4, 2025
-- Recorded Revenues of $35.2 Million for Q3 Fiscal 2025 --
By Lifecore Biomedical, Inc. · Via GlobeNewswire · April 3, 2025

Company Seeking to Remove Convertible Preferred Stock Exchange Cap to Permit Potential Conversion of Series A Preferred Stock as Contemplated by the Series A Preferred Stock Terms
By Lifecore Biomedical, Inc. · Via GlobeNewswire · January 17, 2025

Company Believes it is Well Positioned for Mid-Term and Long-Term Growth asCurrent Capacity Continues to Support up to $300 Million in Annual Revenue
By Lifecore Biomedical, Inc. · Via GlobeNewswire · January 7, 2025

CHASKA, Minn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 43rd Annual J.P. Morgan Healthcare Conference. The conference will take place January 13-16, 2025, in San Francisco, California.
By Lifecore Biomedical, Inc. · Via GlobeNewswire · January 6, 2025

U.S. stock futures were higher on Friday, the slipping in first trading session of 2025. All four index futures advanced in premarket trade.
Via Benzinga · January 3, 2025

US stock futures up, GeneDx appoints new COO, Lifecore beats expectations, SPS Commerce acquires Carbon6, Resources Connection & UDR report strong quarters.
Via Benzinga · January 3, 2025

-- Recorded Revenues of $32.6 Million for Q2 Fiscal 2025 --
By Lifecore Biomedical, Inc. · Via GlobeNewswire · January 2, 2025

The CNN Money Fear & Greed index showed a slight easing in fear, while US stocks closed lower but still recorded gains in 2024.
Via Benzinga · January 2, 2025

Webcast Scheduled for Thursday, January 2 at 4:30 p.m. Eastern
By Lifecore Biomedical, Inc. · Via GlobeNewswire · December 19, 2024

Development Services Span Tech Transfer, Process Assessment and Method Validation for Fill and Finish of NRS-033 for Planned Phase 2 Trial
By Lifecore Biomedical, Inc. · Via GlobeNewswire · December 19, 2024

Three-Year Term Extension Combined with Simplification and Reduction of Interest Rates Helps Further Strengthen Company’s Balance Sheet and Overall Financial Position
By Lifecore Biomedical, Inc. · Via GlobeNewswire · November 26, 2024

CHASKA, Minn., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it hosted a virtual investor day prior to market open during which Lifecore’s senior management team discussed the company’s business and strategy for growth in the future, among other topics. A replay of the event is available via webcast and can be accessed by visiting the Events & Presentations section of Lifecore’s investor web page at: https://ir.lifecore.com/events-presentations.
By Lifecore Biomedical, Inc. · Via GlobeNewswire · November 21, 2024

CHASKA, Minn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that Paul Josephs, the company’s president and chief executive officer, will be a featured speaker in a fireside chat at the upcoming Stephens Annual Investment Conference. The conference is being held November 19-21, 2024, in Nashville, Tennessee.
By Lifecore Biomedical, Inc. · Via GlobeNewswire · November 12, 2024

CHASKA, Minn., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will host a virtual investor day on Thursday, November 21, 2024, prior to market open. The event will take place from 8:00 – 9:30 a.m. Eastern Time and be available via webcast. During the event, members of Lifecore’s senior management team will discuss the company’s business and strategy for growth in the future, among other topics.
By Lifecore Biomedical, Inc. · Via GlobeNewswire · November 7, 2024

Brings Strong Background in Pharmaceutical Manufacturing Operations and Finance to Help Drive Performance and Productivity
By Lifecore Biomedical, Inc. · Via GlobeNewswire · November 4, 2024

Via Benzinga · October 4, 2024

-- Recorded Revenues of $24.7 Million for Q1 Fiscal 2025 --
By Lifecore Biomedical, Inc. · Via GlobeNewswire · October 4, 2024

PIPE with New and Existing Investors Supports Working Capital and Operations
By Lifecore Biomedical, Inc. · Via GlobeNewswire · October 4, 2024